As of 2026-03-26, the EV/EBITDA ratio of Lineage Cell Therapeutics Inc (LCTX) is -6.92. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LCTX's latest enterprise value is 394.20 mil USD. LCTX's TTM EBITDA according to its financial statements is -56.95 mil USD. Dividing these 2 quantities gives us the above LCTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-03-23 | -6.87 |
| 2026-03-20 | -6.77 |
| 2026-03-19 | -7.28 |
| 2026-03-18 | -7.03 |
| 2026-03-17 | -7.44 |
| 2026-03-16 | -7.54 |
| 2026-03-13 | -7.59 |
| 2026-03-12 | -7.44 |
| 2026-03-11 | -7.95 |
| 2026-03-10 | -8.63 |
| 2026-03-09 | -8.42 |
| 2026-03-06 | -8.83 |
| 2026-03-05 | -8.78 |
| 2026-03-04 | -9.35 |
| 2026-03-03 | -9.04 |
| 2026-03-02 | -9.35 |
| 2026-02-27 | -9.19 |
| 2026-02-26 | -9.40 |
| 2026-02-25 | -9.09 |
| 2026-02-24 | -8.68 |
| 2026-02-23 | -8.42 |
| 2026-02-20 | -8.63 |
| 2026-02-19 | -8.47 |
| 2026-02-18 | -8.16 |
| 2026-02-17 | -7.95 |
| 2026-02-13 | -7.85 |
| 2026-02-12 | -8.06 |
| 2026-02-11 | -8.57 |
| 2026-02-10 | -8.78 |
| 2026-02-09 | -7.90 |
| 2026-02-06 | -8.06 |
| 2026-02-05 | -7.95 |
| 2026-02-04 | -8.26 |
| 2026-02-03 | -8.37 |
| 2026-02-02 | -7.23 |
| 2026-01-30 | -6.92 |
| 2026-01-29 | -7.39 |
| 2026-01-28 | -7.44 |
| 2026-01-27 | -7.70 |
| 2026-01-26 | -7.49 |
| 2026-01-23 | -7.59 |
| 2026-01-22 | -7.80 |
| 2026-01-21 | -7.85 |
| 2026-01-20 | -7.80 |
| 2026-01-16 | -8.06 |
| 2026-01-15 | -7.80 |
| 2026-01-14 | -8.06 |
| 2026-01-13 | -7.90 |
| 2026-01-12 | -8.37 |
| 2026-01-09 | -8.11 |